About The Study: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly used for postpartum weight loss since the introduction of semaglutide for weight loss in late 2022. Most users were overweight prior to pregnancy and only 23% had a documented diabetes diagnosis, suggesting that the primary indication for use was weight reduction.
Corresponding Author: To contact the corresponding author, Mette Bliddal, PhD, email mbliddal@health.sdu.dk .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.20947)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.20947?guestAccessKey=09a1fda7-1e2c-4efa-8c4b-5c56cc5722dd&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112425
JAMA